Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objective: Patients submitted to carotid artery endarterectomy (CEA) have a long-term risk of major adverse cardiovascular events (MACE) of 6-9% at 2 years. Hematological parameters have been shown to have a predictive function in atherosclerotic diseases, namely the red blood cell distribution width-coefficient of variation (RDW-CV). This parameter has been associated with worse outcomes such as myocardial infarction (MI), stroke, and all-cause mortality. This study aims to evaluate the potential role of preoperative hematologic parameters such as RDW-CV in predicting perioperative and long-term cardiovascular adverse events and mortality in patients submitted to CEA.
Methods: From January 2012 to January 2019, 180 patients who underwent CEA with regional anesthesia in a tertiary care and referral center were selected from a prospective cohort database. Blood samples were collected preoperatively 2 weeks before admission, including a full blood count. The primary outcome included long-term MACE. Secondary outcomes included all-cause mortality, stroke, MI, acute heart failure, and major adverse limb events (MALE).
Results: At baseline, 27.2% of patients had increased RDW-CV. Increased RDW-CV was independently associated with baseline hemoglobin (adjusted odds ratio [aOR] 0.715, 95% CI 0.588-0.869, p = 0.001) and atrial fibrillation (aOR 4.028, 95% CI 1.037-15.639, p = 0.001). After a median follow-up of 50 months, log-rank univariate analysis of RDW-CV demonstrated a significant association between increased RDW-CV and long-term all-cause mortality (log-rank <0.001), MACE (log-rank <0.001), and MI (log-rank = 0.017). After multivariate Cox regression analysis, increased RDW-CV was associated with increased long-term mortality (adjusted hazard ratio [aHR] 2.455, 95% CI 1.231-4.894, p = 0.011) and MACE (aHR 2.047, 95% CI 1.202-3.487, p = 0.008). A decreased hemoglobin to platelet ratio (aHR 2.650e-8, 95% CI 9.049e-15 to 0.078, p = 0.019) was also associated with all-cause mortality.
Conclusion: RDW is a widely available and low-cost marker that independently predicts long-term mortality, MACE, and MI after CEA. This biomarker could prove useful in assessing which patients would likely benefit from CEA in the long term.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7841742 | PMC |
| http://dx.doi.org/10.1159/000512587 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Transdermal Buprenorphine in the Treatment of Chronic Abdominal Pain Syndrome.
Pain Med Case Rep
December 2023
Department of Anesthesiology, UNC School of Medicine, Chapel Hill, NC.
Background: Centrally mediated abdominal pain syndrome (CAPS) is a condition that has traditionally been treated with first-line agents, such as tricyclic anti-depressants and serotonin and norepinephrine reuptake inhibitors. However, in the setting of pain refractory to these primary agents, there is little evidence in support of alternative regimens, especially opioid analgesics.
Case Report: This case examines the utility of weekly 10 mcg transdermal buprenorphine patches as an additional treatment modality for CAPS, specifically in the setting of a 27-year-old woman with intractable abdominal pain following a cholecystectomy.
Left Sixth Nerve Palsy and Subdural Hygroma Following Intrathecal Morphine Pump Placement: A Case Report.
Pain Med Case Rep
December 2023
University of Central Florida College of Medicine, Orlando, FL.
Background: An intrathecal (IT) pump is an effective drug delivery system that assists patients with chronic pain management. However, due to the invasive nature of the procedure, a complication that could arise is cerebrospinal overdrainage or leak, which could lead to adverse effects.
Case Report: The patient underwent an IT morphine pump implant for treatment of his chronic, intractable low back pain.
Retrospective Analysis of Naltrexone for Persistent Neuropathic Pain Case Series.
Pain Med Case Rep
December 2023
UT Health San Antonio, San Antonio, TX.
Background: Persistent neuropathic pain (NP) is a prevalent and debilitating problem, often resistant to first-line treatment. Low-dose naltrexone (LDN) has shown promise in treating fibromyalgia and other forms of chronic pain.
Case Report: Retrospective analysis was performed on 14 of 18 patients with diverse forms of NP who met inclusion criteria by using LDN (1.
Difficult Single-Lead Spinal Cord Stimulator Trial for Failed Back Surgery Syndrome Salvages Treatment.
Pain Med Case Rep
December 2023
Beth Israel Deaconess Medical Center, Department of Anesthesiology, Critical Care, and Pain Medicine, Harvard Medical School, Boston, MA.
Background: Spinal cord stimulation (SCS) is a minimally invasive neuromodulation treatment modality primarily used for failed back surgery syndrome (FBSS), complex regional pain syndrome, and diabetic neuropathy. Specifically, when utilized for the treatment of FBSS, placement can be complicated by the excessive scarring, adhesions, and altered anatomy limiting the access to the epidural space and advancement of the leads.
Case Report: Our patient is a 58-year-old woman with a history of scoliosis and severe lumbar spinal stenosis who presented for trial of an SCS for FBSS.
Aortoesophageal Fistula Following a Cervical Epidural Steroid Injection: Case Report.
Pain Med Case Rep
December 2023
Department of Anesthesia and Critical Care Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA.
Background: Immunosuppression after cervical epidural steroid injection (CESI) is a potential complication. This report discusses the development of an aortoesophageal fistula following a CESI.
Case Report: Patient is a man in his early 60s with a history of central spinal cord syndrome status post (s/p) anterior cervical discectomy and fusion of C3-C6 and thoracic aortic aneurysm s/p thoracic endovascular aortic repair (TEVAR) who presented with cervical radiculopathy.